ARTICLE | Clinical News
Deutetrabenazine: Phase III data
September 26, 2016 7:00 AM UTC
Top-line data from the modified intent-to-treat (mITT) population of the double-blind, international Phase III AIM-TD trial in 288 patients with moderate to severe tardive dyskinesia showed that once-...